BMO Capital on Structure Therapeutics (GPCR): '"Today's weakness is an attractive entry point into 4Q23'
Tweet Send to a Friend
BMO Capital analyst Evan Seigerman reiterated an Outperform rating and $40.00 price target on Structure Therapeutics (NASDAQ: GPCR)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
